Pomerantz Law Firm Launches Investigation Into LENZ Therapeutics Amid Investor Concerns
Pomerantz Law Firm Investigates LENZ Therapeutics: An Investor Alert
In a recent announcement, Pomerantz LLP has initiated an investigation concerning LENZ Therapeutics, Inc. (NASDAQ: LENZ) following concerns from investors about possible unlawful business practices and securities fraud. Investors affiliated with LENZ are encouraged to reach out to Pomerantz for further information and to explore potential action.
Background of the Investigation
The commencement of this investigation appears timely, as on August 11, 2026, LENZ Therapeutics released its second quarter financial results, which painted a troubling picture. Although the company reported overall revenue of $5.5 million, a significant portion of this figure, amounting to $3.8 million, stemmed from non-product global licensing milestones. Organic product sales, particularly the company's leading eye drop product VIZZ, surprisingly remained stagnant at $1.73 million, which translates to only a 9% growth quarter-over-quarter.
The following day, Bank of America made a notable move by downgrading LENZ's stock from
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.